Y Combinator is doing something that technology accelerators, even those planted firmly in the healthcare space, have traditionally avoided. It will invest in biotech startups.
Technology accelertors never expressed interest in backing biotechnology companies because drug development takes many years, is capital intensive and a high-risk proposition. But the reward is saved or improved lives, so there’s that.
